Wei Xu

Dr. Xu is a Principal Biostatistician at the Princess Margaret Cancer Center, a Scientist at the Ontario Cancer Institute, and an Associate Professor of Biostatistics at Dalla Lana School of Public Health, University of Toronto. As Principal-Investigator or co-Investigator, he has been involved in study design, data administration, statistical modeling development and data analysis on different clinical research and human genetic studies. He has published over 250 peer-reviewed papers in the field of statistics, bioinformatics, medical science and human genetics.

Dr. Xu’s research interests focus on clinical trial design and methodology, biostatistics and bioinformatics methodology, statistical genetics, and cancer clinical and translational research.
FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects.
Gut Microbes. 2018 Mar 13;:1-24
Turpin W, Bedrani L, Espin-Garcia O, Xu W, Silverberg MS, Smith MI, Guttman DS, Griffiths A, Moayyedi P, Panaccione R, Huynh H, Steinhart H, Aumais G, Shestopaloff K, Dieleman LA, Turner D, Paterson AD, Croitoru K
Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma.
Int J Radiat Oncol Biol Phys. 2018 Feb 01;:
Kwan JYY, Su J, Huang SH, Ghoraie LS, Xu W, Chan B, Yip KW, Giuliani M, Bayley A, Kim J, Hope AJ, Ringash J, Cho J, McNiven A, Hansen A, Goldstein D, de Almeida JR, Aerts HJ, Waldron JN, Haibe-Kains B, O'Sullivan B, Bratman SV, Liu FF
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
Cochrane Database Syst Rev. 2018 Jan 25;1:CD003869
Tsao MN, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A, Rakovitch E, Chow E
Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) Practice Guideline.
J Radiosurg SBRT. 2017;5(1):5-24
Tsao MN, Sahgal A, Xu W, De Salles A, Hayashi M, Levivier M, Ma L, Martinez R, Régis J, Ryu S, Slotman BJ, Paddick I
A unified partial likelihood approach for X-chromosome association on time-to-event outcomes.
Genet Epidemiol. 2017 Nov 26;:
Xu W, Hao M
MARK3-mediated phosphorylation of ARHGEF2 couples microtubules to the actin cytoskeleton to establish cell polarity.
Sci Signal. 2017 Oct 31;10(503):
Sandí MJ, Marshall CB, Balan M, Coyaud É, Zhou M, Monson DM, Ishiyama N, Chandrakumar AA, La Rose J, Couzens AL, Gingras AC, Raught B, Xu W, Ikura M, Morrison DK, Rottapel R
Model-Free Linkage Analysis of a Binary Trait.
Methods Mol Biol. 2017;1666:343-373
Xu W, Ma J, Greenwood CMT, Paterson AD, Bull SB
Two BRM Promoter Polymorphisms Predict Poor Survival in Patients with Hepatocellular Carcinoma.
Mol Carcinog. 2017 Sep 11;:
Pasic I, Man Wong K, John Lee J, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown C, Bucur R, Reisman D, Knox JJ, Xu W, Hung RJ, Guo G, Cleary SP
Impact of Type 2 Diabetes Mellitus on Survival in Head and Neck Squamous Cell Carcinoma.
Otolaryngol Head Neck Surg. 2017 Aug 01;:194599817726756
Foreman A, Lee DJ, McMullen C, de Almeida J, Muhanna N, Gama RR, Giuliani M, Liu G, Bratman SV, Huang SH, O'Sullivan B, Song Y, Xu W, Goldstein DP
Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer.
Radiother Oncol. 2017 Aug;124(2):225-231
Hosni A, McMullen C, Huang SH, Xu W, Su J, Bayley A, Bratman SV, Cho J, Giuliani M, Kim J, Ringash J, Waldron J, Spreafico A, Weinreb I, de Almeida JR, Brown DH, Irish JC, O'Sullivan B, Goldstein DP, Hope A

Pages

Scientist, University Health Network

Principal Biostatistician, Princess Margaret Cancer Center, UHN
Associate Professor, Dalla Lana School of Public Health, University of Toronto